Diploma (LON:DPLM – Get Free Report) announced its earnings results on Tuesday. The company reported GBX 255.60 earnings per share (EPS) for the quarter, Digital Look Earnings reports. The business had revenue of GBX 184.03 billion for the quarter. Diploma had a net margin of 9.42% and a return on equity of 18.55%.
Here are the key takeaways from Diploma’s conference call:
- Diploma reported a strong FY2026: organic revenue grew 15%, operating profit rose 42% to £487 million, and EPS increased 45%. Operating margin expanded 400 basis points to 26.5%, with return on capital at 25.3%.
- Management expects another strong year in FY2027, guiding to 6% organic growth and 12% total revenue growth, with further EPS growth. It expects double-digit organic growth in Q1, followed by slower growth in Q2 and Q3 against tougher comparisons.
- The company completed 16 acquisitions since the start of FY2026, investing £368 million and adding about £50 million of annualized operating profit; further deals completed after year-end are expected to contribute to FY2027. Management said its pipeline remains strong, while emphasizing returns discipline and available balance-sheet capacity.
- FY2027 operating margin is forecast at 25.5%, down from 26.5%, reflecting planned investment, lower margins at Peerless and dilution from acquisitions. Management also expects cash conversion to settle around 90% as it invests in inventory to support growth.
- Life Sciences had just 1% organic growth as healthcare markets remained challenging and more products than usual reached the end of their life cycles. Management expects near-term growth to remain modest, while pointing to a healthy longer-term product pipeline.
Diploma Trading Down 1.0%
Shares of DPLM traded down GBX 69.99 during mid-day trading on Wednesday, reaching GBX 6,915.01. The stock had a trading volume of 380,972 shares, compared to its average volume of 2,508,949. Diploma has a 52-week low of GBX 4,970 and a 52-week high of GBX 7,980. The firm has a market cap of £9.27 billion, a price-to-earnings ratio of 49.11, a P/E/G ratio of 2.82 and a beta of 0.92. The business’s fifty day moving average is GBX 7,427.48 and its 200 day moving average is GBX 6,819.16. The company has a debt-to-equity ratio of 47.65, a current ratio of 2.06 and a quick ratio of 0.80.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on DPLM
Key Headlines Impacting Diploma
Investors following DPLM have been watching these headlines:
- Positive Sentiment: FY26 performance was strong: revenue reached £1.84 billion and adjusted operating profit rose 42% to £487.1 million, supported by organic growth and improved margins. The company also increased its dividend, adding to the positive shareholder-return picture. Diploma Reports 42% Rise in Adjusted Operating Profit
- Positive Sentiment: Berenberg Bank reaffirmed its “buy” rating and set a GBX 9,000 price target, indicating substantial upside from the price level in the background information. Berenberg Bank stock recommendations
- Negative Sentiment: Coverage described the shares as pausing after a breakneck 2026 run. That sharp prior advance, alongside uncertainty about FY27, may be prompting investors to reassess expectations and take profits. Diploma pauses for breath following breakneck 2026
Insider Buying and Selling at Diploma
In other news, insider Katie Bickerstaffe purchased 246 shares of the company’s stock in a transaction dated Wednesday, September 23rd. The stock was acquired at an average price of GBX 7,696 per share, with a total value of £18,932.16. 1.14% of the stock is currently owned by company insiders.
About Diploma
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Read More
- Five stocks we like better than Diploma
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.
